We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Maxwell Biosciences, a biotechnology company, announced patented biostable peptide analogs that function as mimics of the cathelicidin peptide - the human body’s primary virus immunity molecule.